title: [Treatment of severe Rhesus erythroblastosis].
abstract: Report about the management of cases of severe Rhesus erythroblastosis. One case is specially discussed because of it's actuality. This was a patient with severe Rh-sensitization (OOD at 450 mm from the beginning of the 30th week of gestation in zone III according to Liley). Because of the haemolytic disease and the chronic fetal distress the Caesarean section was already performed in the 32nd week of gestation after Betamethason treatment of the mother. The Lecithin-Sphingomyelin (L/S) ratio in the amniotic fluid as a criterium of fetal lung maturity raised almost twicefold (from 0.9 to 1.6) after Cortison treatment. The intensive care (assisted ventilation with PEEP, correction of the acidosis and transfusion of packed red cells) of the severely anaemic (Hb 3.5 g%, Hk 15 vol.%) and hydropic newborn was already started in the delivery room. The newborn developed no RDS and was discharged healthy. With reference to this and other cases the management of severe Rh-sensitization before the 34th week of gestation is discussed. Premature infants are mainly susceptable to the development of a Respiratory Distress syndrome (RDS). After antepartum Cortison treatment for prevention of an RDS the date of confinement should be arranged earlier. The value of an early Caesarian section after antepartum Glucocorticoid treatment as compared to the application of intrauterine transfusions in cases of severe erythroblastosis is discussed. It is also reported about recent methods of treatment of severe conditions of hydrops fetalis.
mesh_terms: D001317:Austria; D001805:Blood Transfusion, Intrauterine; D002585:Cesarean Section; D004899:Erythroblastosis, Fetal / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007362:Intensive Care Units; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000175:diagnosis; D012204:Rh-Hr Blood-Group System
chemical_list: D012204:Rh-Hr Blood-Group System
vernacular_title: Zur Behandlung schwerer Rhesus-Erythroblastosen.